New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.
Tiziana Life Sciences expands Phase 2 trial for intranasal foralumab in non-active secondary progressive multiple sclerosis across prominent Northeast institutions.Quiver AI SummaryTiziana Life Sciences,...
Tiziana Life Sciences receives funding from the ALS Association for a clinical trial of intranasal foralumab in ALS patients.Quiver AI SummaryTiziana Life Sciences, a biotechnology company focused on immunomodulation...
EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END
GEVO shareholders may have been sold an empty promise of a sizable share buyback program, or so would bears say. Revenue breakthroughs may deliver the promise
Tesla's price cuts have initiated a full on war across the EV industry, however NIO has refused to follow along. This may present even more upside for the stock
NEW YORK, July 18, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling...
NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling...
NEW YORK, June 17, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling...